Recent developments of interest in cardiovascular medicine
"We are in crisis, and everyone is aware of that." Tough conversations around apparently high cardiovascular surgery mortality and complication rates at North Carolina Children's Hospital in Chapel Hill were captured in secret recordings obtained by The New York Times. (Remember the Florida children's heart surgery program that got shut down?)
A new tool for His-bundle pacing -- the SelectSite C304-HIS deflectable catheter system-- got FDA clearance, Medtronic announced.
The Heart Rhythm Society partnered with Watchman device maker Boston Scientific to promote left atrial appendage closure as an alternative to oral anticoagulation. The company announced the OPTION trial is underway to compare the next-gen Watchman FLX against anticoagulants for stroke prevention in patients getting atrial fibrillation ablation.
Prescription fish oil icosapent ethyl (Vascepa) will get priority review for an expanded indication to reduce residual cardiovascular risk atop a statin when triglycerides remain elevated, with an announcement expected by September 28. (BioPharmaDive)
All SoloPath balloon expandable transfemoral system and re-collapsible balloon access system models and lots are under Class I recall over tip dislodgement, the FDA noted.
Energy drinks altered electrical activity in the heart and raised blood pressure in a placebo-controlled study. (CNN)
New-onset atrial fibrillation affected 50% of patients getting transcatheter or surgical aortic valve procedures in the National Inpatient Sample and 14% versus 31% in a New York State mandatory reporting database. (JAMA Internal Medicine)
Lipoprotein(a) is an independent risk factor for calcific aortic valve stenosis, a genetic variation study showed in JAMA Cardiology.
A case report of chest cavity fire during emergency aortic artery surgery and a study showing more than four-fold heart bypass surgery mortality risk associated with high body fat but no association with BMI made news at the Euroanaesthesia Congress in Vienna. (Live Science, Medical Xpress)
More positive LDL-lowering data on novel oral agent inclisiran came out at the European Atherosclerosis Society Congress in Maastricht, Netherlands, The Medicines Company announced.
At the Heart Failure Congress in Athens:
Zentiva is giving up on European approval for ambrisentan for pulmonary arterial hypertension, the European Medicines Agency announced.
Tafamidis (Vyndaqel), newly approved for transthyretin amyloid cardiomyopathy, made the top five disruptive drugs list for pharmacy network OptumRx.
Read the original article on Medpage Today: Ped Heart Center Woes; His Pacing Tool OK'd; Energy Drink Arrhythmia